Organon & Co
NYSE:OGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Organon & Co
NYSE:OGN
|
US |
|
C
|
Cetus Capital Acquisition Corp
NASDAQ:CETU
|
TW |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
D
|
DigiCo Infrastructure REIT
ASX:DGT
|
AU |
|
Computer Modelling Group Ltd
TSX:CMG
|
CA |
|
Veste SA Estilo
BOVESPA:VSTE3
|
BR |
|
R
|
Richelieu Hardware Ltd
TSX:RCH
|
CA |
|
Jiangsu Yinhe Electronics Co Ltd
SZSE:002519
|
CN |
|
Societe Industrielle et Financiere de l'Artois SA
PAR:ARTO
|
FR |
|
Irisity AB (publ)
F:69M
|
SE |
Multiples-Based Value
The Multiples-Based Value of one
OGN
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 6.12 USD,
Organon & Co
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
OGN Competitors Multiples
Organon & Co Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Organon & Co
NYSE:OGN
|
1.6B USD | 0.3 | 8.5 | 5.7 | 7.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.4 | 16.5 | 7 | 8.6 |